Apimeds Pharmaceuticals US, Inc.: 5%+ holders

As of November 6, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Apimeds Pharmaceuticals US, Inc. The largest reported stake is Inscobee Inc.'s, at 34.3%. 5 filings are on record since January 26, 2026 (Schedule 13D/A, May 7, 2026).

Ayrton Capital LLC also filed stake reports on 31 other companies ↓

Sell to companies like Apimeds Pharmaceuticals US, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Event date 2026-05-07 · Holder: Inscobee Inc. · Percent: 34.3% · Shares: 2,099,747 · SCHEDULE 13D/A
• Filed 2026-03-30 · Holder: Inscobee Inc. · Percent: 34.3% · SCHEDULE 13D/A
• Filed 2026-03-20 · Holder: Inscobee Inc. · Percent: 34.3% · SCHEDULE 13D/A
• Filed 2026-02-11 · Holder: Ayrton Capital LLC · Percent: 9.99% · SCHEDULE 13G
• Filed 2026-01-26 · Holder: Inscobee Inc. · Percent: 34.3% · SCHEDULE 13D/A

Apimeds Pharmaceuticals US, Inc. has 5 Schedule 13D or 13G filings on record since 2026-01-26. 2 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Apimeds Pharmaceuticals US, Inc. and the warning signs.

See Apimeds Pharmaceuticals US, Inc.'s free Snapshot Watch Apimeds Pharmaceuticals US, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Apimeds Pharmaceuticals US, Inc. and the records around it.

Apimeds Pharmaceuticals US, Inc. elsewhere on the record

• IPO filing May 2025
• Who owns it

Companies that share a holder

• Ayrton Capital LLC also filed stake reports on 31 other companies: Bluejay Diagnostics, Inc. (Aug 2026), BTC Digital Ltd. (Aug 2026), DEFSEC Technologies Inc. (Aug 2026)

Want the whole picture on Apimeds Pharmaceuticals US, Inc.?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on Apimeds Pharmaceuticals US, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Apimeds Pharmaceuticals US, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   17 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Purpose of Transaction (Item 4)

Inscobee Inc.

The information set forth in Item 3 of the Schedule 13D is incorporated herein by reference. The Reporting Persons acquired the securities of the Issuer for investment purposes. As previously disclosed, the Reporting Persons engaged in discussions and disputes with the Issuer and certain other parties in connection with, among other things, the Merger Agreement, the Support & Lock-Up Agreement, the Voting Agreements and related transactions. On April 24, 2026, the Reporting Persons and certain other parties entered into a Settlement Agreement (the "Settlement Agreement"), as disclosed in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 4, 2026 (the "Current Report"), pursuant to which the parties agreed to resolve certain disputes relating to the Issuer, the Merger and related transactions. In connection with the Settlement Agreement, the Reporting Persons and certain other parties also entered into (i) a Side Letter Agreement (the "Side Letter") and (ii) a Forbearance Agreement (the "Forbearance Agreement," and together with the Settlement Agreement and Side Letter, the "Settlement Documents"), each as described in the Current Report. The Settlement Documents provide for, among other things: - the resolution of disputes among the parties relating to the Merger and related transactions; - the dismissal of certain litigation and release of claims related to the Merger Agreement, including the dismissal by Erik Emerson of …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-05-07; the filing has the rest

Timeline

Swipe the table sideways to see every column.

Questions about who owns Apimeds Pharmaceuticals US, Inc.

Who owns Apimeds Pharmaceuticals US, Inc.?

On this page, 2 holders' latest ownership filings report 5% or more of Apimeds Pharmaceuticals US, Inc.: Inscobee Inc. (34.3%, Schedule 13D/A, filed 2026-05-07) and Ayrton Capital LLC (9.99%, Schedule 13G, filed 2026-02-11).

Who are the largest shareholders of Apimeds Pharmaceuticals US, Inc.?

By the share each holder's latest filing reports, the largest holders of Apimeds Pharmaceuticals US, Inc. on this page are Inscobee Inc. (34.3%) and Ayrton Capital LLC (9.99%).

When did Inscobee Inc. buy into Apimeds Pharmaceuticals US, Inc.?

The filings give report dates, not purchase dates. The earliest filing from Inscobee Inc. on this page is the Schedule 13D/A, filed 2026-01-26, reporting 34.3%; its latest, Schedule 13D/A filed 2026-05-07, reports 34.3%. That earliest filing is itself an amendment, which updates an earlier report.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 5 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for Apimeds Pharmaceuticals US, Inc.

Swipe the table sideways to see every column.

The newest 12 of 13 records.

Tools for this story

Each opens in a new tab, filled in for Apimeds Pharmaceuticals US, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when Apimeds Pharmaceuticals US, Inc. is mentioned again
• Find former Apimeds Pharmaceuticals US, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes